The Pentagon wants older troops tested for low testosterone

A mandatory blood test is returning to the lives of US service members age 30 and older, even as medical experts question whether many of those tests are needed. The Pentagon has brought back its testosterone deficiency program after pausing an earlier version, but the latest guidance covers male service members only.

That change matters.

The program had first been presented as a broad military health policy. The earlier guidance included women through a questionnaire and possible follow-up care for hormone-related problems. The new clinical guidance does not do that. It sets out testing and treatment steps for male service members and says separate guidance for women will come later.

For the men covered by the policy, testing will be part of routine health checks and annual physical exams. Younger service members may be tested if they ask or if a clinician sees a medical reason. The Pentagon says the new guidance creates a uniform way to screen for and treat testosterone deficiency.

The policy is clear on one point: it is moving ahead.

The medical need is less clear.

Medical experts have described broad testing of service members as unnecessary and potentially harmful. Doctors have also raised concerns that a low test result, especially without clear symptoms, could lead to treatment that a patient does not need. Reuters reported that major medical groups generally tie testosterone treatment to both confirmed deficiency and symptoms, rather than to a test result alone.

That distinction can sound technical. It is not.

A service member is not only a number on a lab report. Training, sleep, stress, illness, diet and other health problems can affect how a person feels and how a test is read. A result may start a chain of follow-up visits, more tests and a discussion of hormone treatment. The program does not require treatment, but it can place a medical label into a person’s record before the need for it is settled.

There are possible harms. Experts have warned that testosterone treatment can carry health risks and may affect fertility when it is used inappropriately. The concern is not that every test will lead to bad care. It is that a system built to test everyone in a broad age group may find problems that are not really problems, then invite treatment before symptoms and cause are understood.

That is a poor place to begin, especially in a military system where service members may feel pressure to accept the direction of the institution.

The Pentagon paused its earlier guidance in September “to allow for updates.” It has now revived the program with a narrower written focus. The department has not made clear what changes were made during the pause. That leaves an ordinary service member with a reasonable question: What did the review settle, and what did it leave unresolved?

The question about women is just as plain.

The latest guidance excludes them from the testing program. The Pentagon says it will issue separate clinical guidance later. Until then, women are outside a formal policy that was once described in broader terms.

There may be sound medical reasons to use different screening methods for men and women. Hormone systems do not work in identical ways, and a single test may not fit every patient. But that explanation has not been fully set out in the policy now being used. What service members can see is a program that moved quickly for men and left women waiting for a separate plan.

That is not automatically unfair. It is, however, unfinished.

Military readiness is a serious goal. The people asked to serve need medical care that helps them stay healthy and able to do their jobs. But readiness should not become a reason to lower the standard for evidence. A policy can sound firm and still be medically weak.

The Pentagon’s case would be stronger if it showed why universal testing is needed, what evidence supports it, how false or borderline results will be handled, and why the approach differs by sex. It should also explain how service members can decline treatment without fear that doing so will affect their standing.

Those are not demands for delay for its own sake. They are basic questions about consent and care.

The original program was paused. That pause suggested the guidance needed work. Its return should therefore bring clearer answers, not only a new effective date.

For now, the facts point in two directions. The Pentagon has created a mandatory testing path for male service members age 30 and older. Medical experts question whether the broad program is necessary and warn that it could cause harm. Women have been left out of the current guidance, with their policy still to come.

That may be a temporary gap. It may also reveal that the department has not yet decided what a fair and medically sound program should look like.

Service members deserve to know which one it is.